These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32016503)

  • 1. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
    Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
    Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
    Xiao L; Joo KI; Lim M; Wang P
    PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
    Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
    Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
    J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming.
    Viscidi RP; Rowley T; Bossis I
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor.
    Eriksson M; Andreasson K; Weidmann J; Lundberg K; Tegerstedt K; Dalianis T; Ramqvist T
    PLoS One; 2011; 6(8):e23828. PubMed ID: 21858228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
    Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
    Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
    Karan D
    Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
    McNeel DG; Dunphy EJ; Davies JG; Frye TP; Johnson LE; Staab MJ; Horvath DL; Straus J; Alberti D; Marnocha R; Liu G; Eickhoff JC; Wilding G
    J Clin Oncol; 2009 Sep; 27(25):4047-54. PubMed ID: 19636017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
    Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
    Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
    Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
    Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer.
    Barr AM; Silva A; Prato S; Belz GT; Maraskovsky E; Baz Morelli A
    Cancer Immunol Immunother; 2020 Oct; 69(10):1959-1972. PubMed ID: 32388678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.